Furthermore, GSK is well known for providing its brand products with a price in Egypt that can be a fraction of its regular price in the region. Of the top 20 multinational corporations working in ...

The 27th Conference of the Parties (COP27) to the United Nation’s Framework Convent on Climate Change was held in Egypt from 6 to ... Claire Lund, GSK’s global VP for sustainability, said ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

despite existing approved products." Tony Wood, Chief Scientific Officer, GSK, said: "We are excited by the early data from IDRX-42 and its unique ability to target all clinically relevant KIT ...

British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work with the University of Oxford on a cancer vaccine research program.

despite existing approved products.' GSK shares were 0.8 per cent lower at 1,339p on Monday morning and have still fallen by around 15 per cent over the past year. Affiliate links: If you take ...

In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal cancer asset. “We really became impressed with what IDRx had achieved ...

China plays a crucial role in Egypt's renewable energy ambitions, said Ghada al-Gendy, executive director of Egypt's Arab ...

Depemokimab data reveals 72% reduction in hospitalizations; projected sales hit £4 billion. GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from ...

Eli Lilly made a $2.5 billion deal for a breast cancer drug; GSK reached a $1 billion-plus deal for IDRx. The announcements suggest a potential rebound in M&A deals in the healthcare sector for 2025.

Q4 2024 Management View CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit ...